COVID-19: Vaccines and Therapeutics
President Biden announced the federal government will purchase an additional 200 million doses of the two COVID-19 vaccines authorized by the Food and Drug Administration for emergency use.
Drug maker Eli Lilly and Company said its neutralizing antibodies cocktail of bamlanivimab and etesevimab combine to significantly reduce hospitalizations and deaths attributed to COVID-19.
Regeneron Pharmaceuticals Inc. announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed.
This year, I look forward to continuing AHA鈥檚 Leadership Rounds, short conversations on trending topics with health care leaders from around the country.
The Centers for Disease Control and Prevention reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million people who received a first dose of the Moderna COVID-19 vaccine between Dec. 21, 2020, and Jan. 10, 2021.
Full-dose blood thinner treatments can reduce the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19, according to interim results from a clinical trial announced by the National Institutes of Health.
鈥淲e have much to do, much to repair, much to restore, much to heal, much to build 鈥 and much to gain.鈥
President Biden today took a number of actions, including signing a series of executive orders (EOs), aimed at addressing the COVID-19 pandemic.
The Food and Drug Administration updated its guidance and webpage on COVID-19 convalescent plasma.